Davidov M E, Glazer N, Wollam G, Zager P G, Cangiano J
Hypertension Research Center, Falls Church, Virginia 22046.
Am J Hypertens. 1988 Jul;1(3 Pt 3):206S-210S. doi: 10.1093/ajh/1.3.206s.
A double-blind, multicenter study compared the safety and efficacy of oral betaxolol 10 to 40 mg once daily (n = 68) with propranolol 40 to 160 mg twice daily (n = 73) in the treatment of mild to moderate essential hypertension. Both agents produced significant (P less than 0.01) and comparable reductions in mean supine systolic and diastolic blood pressures (7/11 mm Hg on betaxolol and 9/10 mm Hg on propranolol). Both betaxolol and propranolol significantly (P less than 0.01) reduced mean supine heart rate by 9 beats per minute. Patients achieved a more significant (P less than 0.01) reduction in blood pressure earlier (weeks 2 and 4 of the titration period) with betaxolol. By the end of treatment there was no significant difference in response between treatment groups. A higher incidence of central nervous system side effects (insomnia, bizarre dreams, depression, hallucinations, dizziness), however, was seen with propranolol than with betaxolol. Overall, the data show that in patients with mild to moderate essential hypertension, betaxolol 10 to 40 mg administered once daily is as effective as and better tolerated than propranolol 40 to 160 mg administered twice daily.
一项双盲、多中心研究比较了每日一次口服10至40毫克倍他洛尔（n = 68）与每日两次口服40至160毫克普萘洛尔（n = 73）治疗轻至中度原发性高血压的安全性和疗效。两种药物均使平均仰卧位收缩压和舒张压显著降低（P<0.01），且降幅相当（倍他洛尔降低7/11毫米汞柱，普萘洛尔降低9/10毫米汞柱）。倍他洛尔和普萘洛尔均使平均仰卧位心率显著降低（P<0.01），每分钟降低9次。在滴定期的第2周和第4周，倍他洛尔使患者血压降低更为显著（P<0.01）。治疗结束时，各治疗组之间的反应无显著差异。然而，普萘洛尔组中枢神经系统副作用（失眠、怪异梦境、抑郁、幻觉、头晕）的发生率高于倍他洛尔组。总体而言，数据表明，对于轻至中度原发性高血压患者，每日一次服用10至40毫克倍他洛尔与每日两次服用40至160毫克普萘洛尔疗效相当，但耐受性更好。
